Evidence map›Paper›PMID 41113484›Full record

ReviewWorld journal of diabetes2025

Anti-inflammatory effects of cannabidiol in the treatment of type 1 diabetes: A mini review.

Victor Augusto Ramos Fernandes, Letícia Ranucci Mendes, Raphael Oliveira Ramos Franco Netto, Felipe Lovaglio Belozo, André Alves Bezerra, Camila Pascoal Correia Dos Santos, Paola Tatiana Espinosa Cruel, Daniela Vieira Buchaim, Rogério Leone Buchaim, Marcelo Rodrigues da Cunha

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Victor Augusto Ramos FernandesDepartment of Health, Jundiaí College of Physical Education, Jundiaí 13202-550, São Paulo, Brazil.
Letícia Ranucci MendesDepartment of Psychology, Centro Universitário Nossa Senhora do Patrocínio, Itu 13300-200, São Paulo, Brazil.
Raphael Oliveira Ramos Franco NettoAmericana Health Department, Family Health Strategy Physician - Mais Médicos Program, Americana 13465-050, São Paulo, Brazil.
Felipe Lovaglio BelozoDepartment of Physical Education, State University of Campinas, Campinas 13083-970, São Paulo, Brazil.
André Alves BezerraDepartment of Morphology, Faculty of Medicine of Jundiaí, Jundiai 13202-550, São Paulo, Brazil.
Camila Pascoal Correia Dos SantosDepartment of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru 17012-901, São Paulo, Brazil.
Paola Tatiana Espinosa CruelDepartment of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru 17012-901, São Paulo, Brazil.
Daniela Vieira BuchaimDepartment of Anatomy, Medical School, University Center of Adamantina, Adamantina 17800-000, Brazil.
Rogério Leone BuchaimDepartment of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru 17012-901, São Paulo, Brazil.
Marcelo Rodrigues da CunhaPostgraduate Program in Health Sciences, Faculty of Medicine of Jundiaí, Jundiaí 13202-550, São Paulo, Brazil. marcelocunha@g.fmj.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study reviews the anti-inflammatory potential of cannabidiol (CBD) in the management of type 1 diabetes (T1D). A comprehensive search was conducted across PubMed, Scopus, and ScienceDirect databases using the terms "type 1 diabetes", "cannabidiol", "anti-inflammatory effect", and "CBD". Articles published between 2005 and 2025 were screened, and studies involving animal models that examined CBD as a therapeutic intervention for T1D and reported on its anti-inflammatory effects were included. Of the 62 retrieved articles, only 6 met the predefined inclusion criteria. Although limited in number, the available studies show promising outcomes. CBD demonstrates potential as an adjuvant therapy for T1D due to its immunomodulatory and anti-inflammatory actions. Nonetheless, further research is required to establish safe and effective clinical application protocols.

Indexed as

BehaviorBehavior mechanismsCannabidiolDiabetes MellitusInflammationsOxidative stressType 1 diabetes

Identifiers

PMID41113484
PMCPMC12531669

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.